This bill significantly amends the Fentanyl Sanctions Act to broaden its scope beyond fentanyl and opioids, focusing on the trafficking of a wider array of illicit substances. A key provision introduces new definitions for "copy-cat ingredients" —substances designed to mimic approved prescription drug components but manufactured differently or with lower quality—and incorporates existing definitions for "counterfeit drugs" into the act's enforcement framework. The legislation systematically replaces terms like "opioid" and "fentanyl" with "illicit drug" throughout the Fentanyl Sanctions Act, ensuring that its provisions, including those related to foreign illicit drug trafficking, apply to a more comprehensive range of dangerous substances. This expansion aims to enhance the government's ability to combat the illicit trade of these harmful products. Additionally, the bill grants the Director of National Intelligence the authority to delegate responsibilities concerning the identification of foreign drug traffickers and related briefings, streamlining intelligence operations. Furthermore, the Act clarifies a waiver provision for access to prescription medications, specifying that such waivers are applicable only to medications listed on the official drug shortage list maintained by the Secretary of Health and Human Services. These changes collectively strengthen the legal framework for disrupting the supply chains of various illicit and counterfeit pharmaceuticals.